Drug resistant superbugs are killing 33,000 in Europe each year

[November 06, 2018]  LONDON (Reuters) - Superbug infections resistant to multiple antibiotics kill around 33,000 people a year in Europe, health experts said on Monday, and the burden of these diseases is comparable to that of flu, tuberculosis and HIV combined.

An analysis by the European Center for Disease Prevention and Control (ECDC) found the impact of drug-resistant infections had increased since 2007, with concerning rises in cases of bugs resistant to even the most powerful, last-resort antibiotics - including a class of drugs known as carbapenems.

"This ... is worrying because these antibiotics are the last treatment options available," the ECDC said in a statement. "When these are no longer effective, it is extremely difficult or, in many cases, impossible to treat infections."

Specialists estimate that around 70 percent of bacteria that can cause infection are already resistant to at least one antibiotic that is commonly used to treat them.

This has made the evolution of "superbugs" that can evade one or multiple drugs one of the biggest threats facing medicine today.

 

The ECDC study, published in the Lancet Infectious Diseases journal, focused on five types of infections caused by antibiotic-resistant bacteria in the European Union and in the European Economic Area (EU/EEA).

It found that around 75 percent of the burden of superbug disease is due to infections contracted in hospitals and health clinics - known as healthcare-associated infections (HAIs).

"Strategies to prevent and control antibiotic-resistant bacteria require coordination at EU/EEA and global level," it said. It added that due to variations in the numbers of cases and the types of antibiotic-resistant bacteria causing infection in different countries, prevention and control measures need to be tailored to national situations.

(Reporting by Kate Kelland; Editing by Mark Potter)

[© 2018 Thomson Reuters. All rights reserved.]

Copyright 2018 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.